Stroke Trials Registry

GV150526
Gavestinel

Action
Glutamate antagonist (NMDA receptor blocker at glycine site)

Status
GAIN-1 trial completed. Phase III trials in Europe and Americas have been completed; preliminary results show no therapeutic effect; results published 2000, 2001. Company halted development of GV 150526 for stroke 5/2/00.

Trial(s)
= Ongoing
= Completed

GAIN 1 Glycine Antagonist in Neuroprotection-1

GAIN 2 Glycine Antagonist in Neuroprotection-2

GAIN Americas Glycine Antagonist in Neuroprotection for Patients with Acute Stroke

GAIN International Glycine Antagonist in Neuroprotection for Patients with Acute Stroke

Safety and Tolerability of GV150526 in Patients With Acute Stroke

Web Links and Publications

Glaxo Wellcome Web Site.

Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial.
JAMA 2001 Apr 4;285(13):1719-28.

Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke.
Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):867-72.

Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators.
Lancet. 2000 Jun 3;355(9219):1949-54.

Phase II studies of the glycine antagonist GV150526 in acute stroke : the North American experience. The North American Glycine Antagonist in Neuroprotection (GAIN) Investigators.
Stroke 2000 Feb;31(2):358-65.

Gavestinel. GV 150526, GV 150526A.
Drugs R D 1999 Jan;1(1):23-4

Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke.
Stroke 1999 May;30(5):986-92.

UID: 24